Prevalence of Subclinical Amyloidosis in a Cross-sectional Study of Egyptian RA Patients without Proteinuria

Author(s): Hassan Bassiouni*, Ahmed El-Atrebi, Khaled Zaky, Hoda Abou-Gabal.

Journal Name: Current Rheumatology Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Amyloidosis is a life-threatening complication of Rheumatoid Arthritis (RA) that should be detected as early as possible to avoid its morbidity and mortality.

Objective: To detect subclinical amyloidosis in RA patients without proteinuria and a disease duration more than 5 years.

Patients: Eighty-six RA patients seen between October 2013 and August 2014 were recruited for the study. Those with 5 years disease duration were included in the study but those who had proteinuria, serum creatinine > 1.5 mg/dl, disease onset before the age of 16 years or improper specimens, were excluded, leaving 30 eligible patients (23 women, 7 men). The clinical, laboratory and imaging results and treatments were maintained for each patient. Abdominal Fat Aspiration Biopsy (AFAB) was performed on all 30 patients. Amyloid deposits were spotted by polarised light microscopy following Congo red staining. Informed consent was acquired from all patients. Clinical disease activity was scored according to DAS. ELISA measured serum amyloid A protein (SAA), CRP and RF.

Results: AFAB stained positive for amyloid in 4 (13.3%) patients out of 30. The amyloid deposits were (1+) in 1 patient and (2+) in 3 patients. Longer RA duration correlated positively with amyloidosis (12.50 years versus 6.15years) (P < 0.001). Extra-articular manifestations were present in 50% of the amyloid patients and in 15.3% of the non-amyloid patients. This difference was significant (P < 0.01). DAS 28 score was higher in amyloid patients (P < 0.001). No difference was found between amyloid and non-amyloid patients regarding age, sex or deformities. SAA was significantly higher in amyloid patients (P < 0.001). However, haemoglobin levels were found to be significantly lower in amyloid patients (P < 0.001).

Conclusion: The prevalence of subclinical amyloidosis by AFAB was found to be (13.3%). The use of AFAB should be encouraged, particularly in patients with longer disease duration and low haemoglobin level to confirm early detection of subclinical amyloidosis.

Keywords: Abdominal fat aspiration biopsy, secondary amyloidosis, subclinical amyloidosis, RA, proteinuria, prevalence.

[1]
Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29(6): 706-14.
[2]
Mutru O, Laakso M, Isomäki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985; 290(6484): 1797-9.
[3]
Gómez-Casanovas E, Sanmartí R, Solé M, Cañete JD, Muñoz-Gómez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis: A systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44(1): 66-72.
[4]
Ayar Y, Ersoy A, Oksuz MF, et al. Clinical outcomes and survival in AA amyloidosis patients. Rev Bras Reumatol Engl Ed 2017; 57(6): 535-44.
[5]
Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience. Am J Med 1987; 82(3): 412-4.
[6]
Roselló R, Solé M. La biopsia de la grasa subcutánea abdominal en el diagnóstico de amiloidosis. Med Clin (Barc) 1985; 85(17): 691-4.
[7]
Klemi PJ, Sorsa S, Happonen RP. Fine-needle aspiration biopsy from subcutaneous fat. An easy way to diagnose secondary amyloidosis. Scand J Rheumatol 1987; 16(6): 429-31.
[8]
Breedveld FC, Markusse HM, MacFarlane JD. Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic arthritis. Clin Exp Rheumatol 1989; 7(4): 407-10.
[9]
Shidham VB, Hunt B, Jaradeh SS. Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp 2010; 44: 2-8.
[10]
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26(3): 743-5.
[11]
Hazenberg BP, Bijzet J, Limburg PC, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14(2): 133-40.
[12]
Esmail RS, Sharaf Walid M, Helmy Noha A, et al. Screening of BRCA1 mutations using c-terminal antibody in sporadic non familial colonic carcinoma. Maced J Med Sci 2012; 5(54): 377-81.
[13]
XXIVth CINP Congress: Paris, France, 20-24 June 2004 The International Journal of Neuropsychopharmacology, 06 2004.
[14]
Mahfouz SM. Wafaa E AbdEl-Aal, Hanan HM Ali, Ahmed El- Habashi, and Reham SE Esmail "Galectin-3 and MCM2 expression in fine-needle aspiration cytology of thyroid nodules and their preoperative role in distinguishing benign from malignant thyroid lesions 2012.
[15]
Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003; 30(5): 948-51.
[16]
El Mansoury TM, Hazenberg BP, El Badawy SA, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: Clinical and laboratory characteristics. Ann Rheum Dis 2002; 61(1): 42-7.
[17]
Päi S, Helin H, Isomäki H. Frequency of amyloidosis in Estonian patients with rheumatoid arthritis. Scand J Rheumatol 1993; 22(5): 248-9.
[18]
Tiitinen S, Kaarela K, Helin H, Kautiainen H, Isomäki H. Amyloidosis--incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 1993; 22(4): 158-61.
[19]
Wiland P, Wojtala R, Goodacre J, Szechinski J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol 2004; 23(3): 193-8.
[20]
Alishiri GH, Salimzadeh A, Owlia MB, Forghanizadeh J, Setarehshenas R, Shayanfar N. Prevalence of amyloid deposition in long standing rheumatoid arthritis in Iranian patients by abdominal subcutaneous fat biopsy and assessment of clinical and laboratory characteristics. BMC Musculoskelet Disord 2006; 7: 43.
[21]
Younes M, Korbaa W, Moussa A, et al. Prevalence of subclinical amyloidosis in Tunisian patients with rheumatoid arthritis. Joint Bone Spine 2009; 76(3): 254-9.
[22]
Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis Rheum 2009; 61(10): 1435-40.
[23]
Hachulla E, Grateau G. Moyens paracliniques de diagnostic des amyloses. Rev Rhum 2002; 69: 1172-80.
[24]
Fiter J, Nolla JM, Valverde J, Roig Escofet D. Methotrexate treatment of amyloidosis secondary to rheumatoid arthritis. Rev Clin Esp 1995; 195(6): 390-2.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [162 - 167]
Pages: 6
DOI: 10.2174/1874471011666180903164014
Price: $58

Article Metrics

PDF: 47
HTML: 2